Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 6,226.0 | 5,886.0 | 5,625.0 | 4,258.0 | 4,277.0 | 3,948.0 | 3,704.0 | 3,403.0 |
| Revenue growth | 5.8% | 4.6% | 32.1% | -0.4% | 8.3% | 6.6% | 8.8% | -2.8% |
| Cost of goods sold | 104.0 | 109.0 | 107.0 | 97.0 | 95.0 | 94.0 | 86.0 | 85.0 |
| Gross profit | 6,122.0 | 5,777.0 | 5,518.0 | 4,161.0 | 4,182.0 | 3,854.0 | 3,618.0 | 3,318.0 |
| Gross margin | 98.3% | 98.1% | 98.1% | 97.7% | 97.8% | 97.6% | 97.7% | 97.5% |
| Selling, general and administrative | | | | | | | | |
| Sales and marketing | 51.0 | 57.0 | 39.0 | 39.0 | 37.0 | 31.0 | 30.0 | 28.0 |
| Research and development | 207.0 | 186.0 | 151.0 | 133.0 | 127.0 | 125.0 | 111.0 | 107.0 |
| General and administrative | 1,268.0 | 1,167.0 | 1,065.0 | 959.0 | 976.0 | 905.0 | 891.0 | 213.0 |
| EBITA | 1,845.0 | 1,781.0 | 1,488.0 | 1,271.0 | 1,176.0 | 1,142.0 | 459.0 | 981.0 |
| EBITA margin | 29.6% | 30.3% | 26.5% | 29.8% | 27.5% | 28.9% | 12.4% | 28.8% |
| Amortization of intangibles | 153.0 | 170.0 | 103.0 | 101.0 | 109.0 | 92.0 | 82.0 | 62.0 |
| EBIT | 1,692.0 | 1,611.0 | 1,385.0 | 1,170.0 | 1,067.0 | 1,050.0 | 377.0 | 919.0 |
| EBIT margin | 27.2% | 27.4% | 24.6% | 27.5% | 24.9% | 26.6% | 10.2% | 27.0% |
| Pre-tax income | 1,475.0 | 1,534.0 | 1,212.0 | 1,019.0 | 1,064.0 | 872.0 | 133.0 | 630.0 |
| Income taxes | 352.0 | 347.0 | 279.0 | 245.0 | 606.0 | 143.0 | 27.0 | 203.0 |
| Tax rate | 23.9% | 22.6% | 23.0% | 24.0% | 57.0% | 16.4% | 20.3% | 32.2% |
| Net income | 1,125.0 | 1,187.0 | 933.0 | 774.0 | 458.0 | 729.0 | 106.0 | 428.0 |
| Net margin | 18.1% | 20.2% | 16.6% | 18.2% | 10.7% | 18.5% | 2.9% | 12.6% |
| |
| Diluted EPS | $2.26 | $2.35 | $1.86 | $4.64 | $2.73 | $4.30 | $0.63 | $2.50 |
| Shares outstanding (diluted) | 497.9 | 505.1 | 500.7 | 167.0 | 167.7 | 169.6 | 168.8 | 171.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|